2022 World Conference on Lung Cancer (ePosters)-EP14.01-016. Anlotinib Plus Toripalimab as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer: a Single-Arm Phase II Study

EP14.01-016. Anlotinib Plus Toripalimab as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer: a Single-Arm Phase II Study

Back to course

Pdf Summary

A phase II study conducted in China evaluated the efficacy and safety of anlotinib plus toripalimab as maintenance treatment in patients with extensive-stage small cell lung cancer (ES-SCLC) after first-line chemotherapy. The study aimed to delay disease recurrence and improve survival outcomes. <br /><br />The study enrolled 15 patients with ES-SCLC who had completed 4 to 6 cycles of first-line platinum-based chemotherapy and had an ECOG performance status of 0-1. Anlotinib was administered orally at a dose of 12mg daily for 14 days every 3 weeks, and toripalimab was given intravenously at a dose of 240mg every 3 weeks until disease progression or treatment intolerance.<br /><br />The primary endpoints of the study were progression-free survival (PFS) and overall survival (OS), while secondary endpoints included objective response rate (ORR), disease control rate (DCR), and time to response (TTR). <br /><br />The results showed that among the 15 patients, 1 patient (6.7%) achieved a partial response, 11 patients (73.3%) had stable disease, and 3 patients (20.0%) had progressive disease. The ORR was 6.7% and the DCR was 80.0%. The median PFS was 12.5 months.<br /><br />The treatment regimen of anlotinib plus toripalimab demonstrated significant efficacy and manageable toxicities as maintenance treatment in patients with ES-SCLC after first-line chemotherapy. The most common grade 1-2 treatment-related adverse events were rash, weakness, leukopenia, poor appetite, hypothyroidism, hoarse voice, oral mucositis, and headache. Grade 3 treatment-related adverse events included hypothyroidism, rash, myalgia, and radiation pneumonia.<br /><br />In conclusion, anlotinib plus toripalimab as maintenance treatment showed promise in delaying disease recurrence and prolonging survival times in patients with ES-SCLC after first-line chemotherapy. This combination provides a new treatment strategy for this patient population. However, further research is needed to fully understand the efficacy and safety profile of this regimen.

Asset Subtitle

Dongqing Lv

Meta Tag

Speaker Dongqing Lv

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

anlotinib

toripalimab

maintenance treatment

small cell lung cancer

chemotherapy

progression-free survival

overall survival

adverse events

disease recurrence

survival outcomes